• Cansu G Genç, Anneke P Jilesen, Stefano Partelli, Massimo Falconi, Francesca Muffatti, Folkert J van Kemenade, Susanne van Eeden, Joanne Verheij, Susan van Dieren, Casper H J van Eijck, and Elisabeth J M N... more ieveen van Dijkum. less
• *Department of Surgery, Academic Medical Center, Amsterdam, the Netherlands†Pancreatic Surgery Unit, Pancreas Translational & Research Institute, Scientific Institute San Raffaelle Hospital & Unive... more rsity Vita e Salute, Milano, Italy‡Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands§Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands¶Department of Methodology and Statistic CRU, Academic Medical Center, Amsterdam, the Netherlands||Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands. less
• Ann. Surg. 2017 Jan 3.

ObjectiveThe aim of this study was to predict recurrence in patients with grade 1 or 2 nonfunctioning pancreatic neuroendocrine tumors (NF-pNET) after curative resection.BackgroundSurgical resection is the preferred treatment for NF-pNET; however, recurrence occurs frequently after curative surgery, worsening prognosis of patients.MethodsRetrospectively, patients with NF-pNET of 3 institutions were included. Patients with distant metastases, hereditary syndromes, or grade 3 tumors were excluded. Local or distant tumor recurrence was scored. Independent predictors for survival and recurrence were identified using Cox-regression analysis. The recurrence score was developed to predict recurrence within 5 years after curative resection of grade 1 to 2 NF-pNET.ResultsWith a median follow-up of 51 months, 211 patients with grade 1 to 2 NF-pNET were included. Thirty-five patients (17%) developed recurrence. The 5- and 10-year disease-specific/overall survival was 98%/91% and 84%/68%, respectively. Predictors for recurrence were tumor grade 2, lymph node metastasis, and perineural invasion. On the basis of these predictors, the recurrence score was made. Discrimination [c-statistic 0.81, 95% confidence interval (95% CI) 0.75-0.87] and calibration (Hosmer Lemeshow Chi-square 11.25, P = 0.258) indicated that the ability of the recurrence score to identify patients at risk for recurrence is good.ConclusionsThis new scoring system could predict recurrence after curative resection of grade 1 and 2 NF-pNET. With the use of the recurrence score, less extensive follow-up could be proposed for patients with low recurrence risk. For high-risk patients, clinical trials should be initiated to investigate whether adjuvant therapy might be beneficial. External validation is ongoing due to limited availability of adequate cohorts.

18 keywords...

hide…